Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
March 2016, Vol 7, No 2
March 2016, Vol 7, No 2
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
By
Lisa A. Raedler, PhD, RPh
Drug Updates
March 2016, Vol 7, No 2
There is an urgent unmet need for more effective therapies in pancreatic cancer. The American Cancer Society estimated that approximately 49,000 new cases of pancreatic cancer will be diagnosed in the United States in 2015, and more than 40,500 people will die from this cancer.
1
Pancreatic cancer is the fourth most common cause of cancer deaths in the United States.
Read Article
New Survey: Physicians Are Not Addressing Financial Distress in Patients with Multiple Myeloma
By
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Patients with multiple myeloma are making significant lifestyle trade-offs to manage the cost of healthcare, according to findings from the Cancer Experience Registry presented at ASH 2015. Joanne S. Buzaglo, PhD, Senior Vice President, Research and Training, Cancer Support Community, Philadelphia, PA, discussed survey results of patients with multiple myeloma who are assuming more costs, including direct costs (ie, copays and prescriptions) and indirect costs (ie, transportation costs and loss of income), which is leading to financial distress.
Read Article
A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities
By
Chase Doyle
Survivorship
,
Policies & Guidelines
March 2016, Vol 7, No 2
A new paradigm of survivorship care is needed that attempts to balance the patient’s total well-being against the often toxic treatment of the disease, suggests Deborah Korenstein, MD, Director of Clinical Effectiveness, Memorial Hospital, Memorial Sloan Kettering Cancer Center, NY. At the 2016 Cancer Survivorship Symposium, Dr Korenstein outlined a more personal approach to care: assessing the individual patient’s priorities and goals to balance long-term benefits and harms.
Read Article
Regular Aspirin Use Reduces the Risk for Prostate Cancer Death
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer, according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium. For the purposes of this study, lethal prostate cancer was defined as metastatic disease or prostate cancer–specific death.
Read Article
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study (Friedenreich CM, et al.
Eur Urol
. 2016 Jan 7. Epub ahead of print).
Read Article
Myeloablative Conditioning Remains Standard of Care in Patients with Myelodysplastic Sydrome
By
Phoebe Starr
Hematologic Malignancies
,
Myelodysplastic Syndromes
March 2016, Vol 7, No 2
Traditional myeloablative conditioning remains the standard of care for preparing patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) for transplant, according to a randomized trial from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The study, presented as a late-breaker at ASH 2015, was halted after a reduced-intensity conditioning (RIC) regimen proved less effective.
Read Article
Rituximab Boosts Chemotherapy Benefit in Patients with B-Cell Precursor ALL
By
Dana Taylor
Hematologic Malignancies
,
Leukemia
March 2016, Vol 7, No 2
In patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the addition of rituximab (Rituxan) to chemotherapy significantly improved event-free survival in a large European study.
Read Article
Pembrolizumab Shows Promise in Multiple Myeloma
By
Dana Taylor
Hematologic Malignancies
,
Multiple Myeloma
March 2016, Vol 7, No 2
Monoclonal antibodies targeting PD-1 may be effective in multiple myeloma, according to early data from 2 clinical trials on pembrolizumab (Keytruda) presented at ASH 2015.
Read Article
Big Data in Cancer Care: Limitations of Drug Claims
By
Catherine E. Cooke, PharmD, BCPS
;
F. Randy Vogenberg, PhD, RPh, FASHP
Cancer Care
,
Employers’ Perspective
,
Value Peer-spectives
March 2016, Vol 7, No 2
As one part of an ongoing macrotheme regarding big data, understanding the benefits and limitations of using drug claims in employer-based population health is an important topic for employers in their health plan coverage strategies. Pharmacy claims are a common source of data used to describe the uses of cancer medications by employees and by their covered family members. Despite the availability of these data and a plethora of analyses, however, several limitations must be considered when interpreting drug use data.
Read Article
Clinical Advances with Targeted Therapies for CLL Also Carry High Economic Burden
By
Chase Doyle
Value in Oncology
March 2016, Vol 7, No 2
Oral targeted therapies, such as ibrutinib (Imbruvica) and idelalisib (Zydelig), represent a major advance for patients with chronic lymphocytic leukemia (CLL) and have undoubtedly changed the treatment paradigm for this disease and the clinical outcomes.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma